• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 17 of 100
person standing in front of a countdown clock in front of Paris's Eiffel Tower
LifestyleGen X drugmaker is coughing up millions for Paris Olympics sponsorship to show Gen Z and millennials it’s a cool place to work
By Prarthana PrakashJanuary 10, 2024
HealthAlphabet’s Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery
By Susanne Barton and BloombergJanuary 8, 2024
Boston Scientific headquarters as pictured on Jan. 19, 2007. The company acquired device-maker Axonics Inc. for $2.7 billion on Monday.
HealthJ&J, Merck, Boston Scientific go on $6.4B buying spree
By Fiona Rutherford and BloombergJanuary 8, 2024
Eli Lilly and Company says its popular drugs Mounjaro and Zepbound, also known as GLP-1s, are not meant for those without obesity or type 2 diabetes.
HealthEli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of for diabetes and obesity
By Alexa MikhailJanuary 4, 2024
HealthOzempic, Wegovy demand so strong Europe’s most valuable listed company plans ‘mega manufacturing facility’
By Ellie Harmsworth and BloombergDecember 24, 2023
HealthPharma will pay rebates in 2024 on 48 drugs whose prices rose more than inflation this year: ‘Let’s call this for what it is—it simply is a rip off’
By Amanda Seitz and The Associated PressDecember 15, 2023
NewslettersWhy business should pay attention to the Supreme Court’s latest mifepristone case
By Emma Hinchliffe and Joey AbramsDecember 14, 2023
CommentaryClimate change is unleashing a tsunami of infectious diseases–and we have fewer and fewer drugs that can treat them
By Jayasree K. IyerDecember 11, 2023
Joe Biden
PoliticsThe White House threatens to cancel the patents of taxpayer-funded drugs if they’re too expensive for patients to afford
By Amanda Seitz, Zeke Miller and The Associated PressDecember 7, 2023
NewslettersEli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options
By Sheryl EstradaNovember 29, 2023
McLaren Racing boss Zak Brown
LeadershipHow the high-stakes world of Formula 1 racing inspired Sanofi CEO Paul Hudson to deliver more medicines
By Christiaan HetznerNovember 27, 2023
FinanceBiden administration is cracking down on pharmacy middlemen, but they’re so powerful it might be too late to help independent drugstores
By Arthur Allen and KFF Health NewsNovember 16, 2023
CommentaryOur changing climate is jeopardizing worker health and productivity. Companies need to adapt their operations
By Martine Ferland and Judy MonroeNovember 15, 2023
HealthEurope’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.
By Ryan HoggNovember 6, 2023
MindJust 1 sleepless night could actually lead to a dopamine boost—and reverse depression for several days
By Erin PraterNovember 3, 2023
1...
  • 15
  • 16
  • 17
  • 18
  • 19
...100
Most Popular
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’An image of a popular article
By Emma BurleighFebruary 2, 2026
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House postAn image of a popular article
By Eleanor PringleFebruary 4, 2026
Investing
Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the boardAn image of a popular article
By Jim EdwardsFebruary 4, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.